Poland· PL-100351015

Adenosine Kabi

A adenosine product containing adenosinum, registered in Poland by Fresenius Kabi Polska Sp. z o.o.. The same ATC class is registered in 16 of our 19 countries.

ATC C01EB10

Checked against URPL (Poland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about adenosinumAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Adenosine is registered in 16 of 19 countries.

Countries holding a registration under ATC C01EB10 (adenosine), each read from that country’s own register.

This record: Poland, from URPL (Poland)
8 of them publish a price we can compare per daily dose

Search adenosine products by name

Adenosine · ATC C01EB10

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)

Active substance: Adenosinum
Manufacturer: Fresenius Kabi Polska Sp. z o.o.
Country: Poland (PL)
ATC code: C01EB10
ATC class: Adenosine
Defined daily dose: 15 mg, P
Reimbursed: Not published by this register
Source register: URPL (Poland)
Last checked: September 27, 2026

Packs & prices · 9

gtin
05909991253554
gtin
05909991253561
gtin
05909991253578
gtin
05909991253585
gtin
05909991253592
gtin
05909991253608
gtin
05909991253615
gtin
05909991253622
gtin
05909991253639

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

181 interactions on record for adenosine.

Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check adenosine against other medicines How interaction checks work

Adenosine · interactions on record

181 records

38 severe
90 moderate
1 minor
52 info

Most severe, free to view

PapaverineA03AD01severe
CisaprideA03FA02severe
DolasetronA04AA04severe
PapaverinC04AX38severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Adenosine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All adenosine products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

Austria · Adenosin Baxter, Adenosin Hikma
Belgium · Adenocor, Adenosine Fresenius Kabi
Cyprus · Caden
Czechia · Adenocor
Germany · Adenoscan, Adenosin Altamedics
Denmark · Adenocor, Adenosin Fresenius Kabi
Estonia · Adenosin Life Medical
Spain · Adenocor, Adenoscan
Finland · Adenosin Life Medical, Adenosin Macure
France · Adenoscan, Adenosine Hikma
United Kingdom (Northern Ireland) · Adenocor, Adenoscan
Greece · Adenorythm
Hungary · Adenocor
Ireland · Adenocor, Adenosine
Italy · Adenoscan, Adenosina Hikma
Lithuania · Adenosine Life Medical
Luxembourg · Adenocor
Netherlands · Adenocor, Adenosine Fresenius Kabi
Norway · Adenosin Life Medical, Adenosin Macure
Portugal · Adenoscan, Adenosina Baxter
Sweden · Adenosin Life Medical, Adenosin Macure
Slovakia · Adenocor

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/e4c24122-51e4-4f52-bd9b-1e002f87c646
GET /v1/drugs/e4c24122-51e4-4f52-bd9b-1e002f87c646?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "3 mg/ml",
  "packaging": "05909991253554 ¦ Lz ¦ 112962\n1 amp.-strzyk. 4 ml\n05909991253561 ¦ Lz ¦ 112963\n1 amp.-strzyk. 1 ml\n05909991253578 ¦ Lz ¦ 112964\n1 amp.-strzyk. 2 ml\n05909991253585 ¦ Lz ¦ 112965\n6 amp.-strzyk. 4 ml\n05909991253592 ¦ Lz ¦ 112966\n6 amp.-strzyk. 2 ml\n05909991253608 ¦ Lz ¦ 112967\n6 amp.-strzyk. 1 ml\n05909991253615 ¦ Lz ¦ 112968\n10 amp.-strzyk. 4 ml\n05909991253622 ¦ Lz ¦ 112969\n10 amp.-strzyk. 1 ml\n05909991253639 ¦ Lz ¦ 112970\n10 amp.-strzyk. 2 ml",
  "substance": "Adenosinum 3 mg/ml",
  "common_name": "Adenosinum",
  "pl_product_id": "100351015",
  "pozwolenie_nr": "22867",
  "auth_procedure": "DCP",
  "authorisation_validity": "2025-01-16"
}

API reference MCP server Plans

See everything about adenosine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console